Format

Send to

Choose Destination
Brain Res. 2015 Oct 14;1623:30-8. doi: 10.1016/j.brainres.2015.04.024. Epub 2015 Apr 25.

Matrix metalloproteinases as therapeutic targets for stroke.

Author information

1
Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
2
Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. Electronic address: grosenberg@salud.unm.edu.

Abstract

Matrix metalloproteinases (MMPs) are important in injury and recovery in ischemic injury. They are proteolytic enzymes that degrade all components of the extracellular matrix (ECM). They are secreted in a latent form, protecting the cell from damage, but once activated induce injury prior to rapid inactivation by four tissue inhibitors to metalloproteinases (TIMPs). Normally the constitutive enzymes, MMP-2 and membrane type MMP (MMP-14), are activated in a spatially specific manner and act close to the site of activation, while the inducible enzymes, MMP-3 and MMP-9, become active through the action of free radicals and other enzymes during neuroinflammation. Because of the complex nature of the interactions with tissues during development, injury and repair, the MMPs have multiple roles, participating in the injury process in the early stages and contributing to recovery during the later stages. This dual role complicates the planning of treatment strategies. This article is part of a Special Issue entitled SI: Cell Interactions In Stroke.

KEYWORDS:

Angiogenesis; Blood–brain barrier; Hypoxia/ischemia; Matrix metalloproteinases; Recovery

PMID:
25916577
PMCID:
PMC4569515
DOI:
10.1016/j.brainres.2015.04.024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center